Axsome Therapeutics (AXSM) Fundamental Analysis: Revenue, Earnings & Valuation

0.98 / 10

Underperform

Fundamentally, AXSM scores 1/10, indicating underperformance. Inventory turnover (2.174) and cost‑of‑sales ratio (7.44%) are strong, but long‑term debt to working capital (1.06) and PB‑ROE (11.84) are weak. Revenue‑MV and Asset‑MV are negative, limiting valuation upside.

Analysis Checks(6/10)

Revenue-MV

Value-1.53

Score1/3

Weight45.41%

1M Return4.09%

Total operating revenue (YoY growth rate %)

Value65.55

Score2/3

Weight1.26%

1M Return0.13%

Inventory turnover ratio

Value2.17

Score3/3

Weight-8.98%

1M Return-0.93%

Current liabilities / Total liabilities (%)

Value62.98

Score2/3

Weight3.53%

1M Return0.36%

PB-ROE

Value11.84

Score0/3

Weight30.81%

1M Return2.74%

Long-term debt to working capital ratio (%)

Value1.06

Score1/3

Weight-6.15%

1M Return-0.65%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-10.60%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value65.55

Score2/3

Weight0.51%

1M Return0.05%

Cost of sales ratio (%)

Value7.44

Score3/3

Weight2.65%

1M Return0.26%

Asset-MV

Value-0.55

Score0/3

Weight41.56%

1M Return4.00%

Is AXSM fundamentally strong?

AXSM scores 0.98/10 on fundamentals and holds a Premium valuation at present. Backed by its -252.11% ROE, -28.69% net margin, -47.20 P/E ratio, 97.92 P/B ratio, and 38.56% earnings growth, these metrics solidify its Underperform investment rating.